Physicians' Academy for Cardiovascular Education

Long-term PCSK9 inhibitor safe and effective in HeFH

Long-term Safety, Tolerability, and Efficacy of Evolocumab in Patients With Heterozygous Familial Hypercholesterolemia

Literature - Hovingh GK, Raal FJ, Dent R, et al. - J Clin Lipidol (2017), doi: 10.1016/j.jacl.2017.09.003

Main results

Conclusion

This open-label extension trial of evolocumab demonstrated that long-term use (48 weeks) of this PCSK9 inhibitor in combination with SOC reduced the levels of LDL-C and was well tolerated in a HeFH patient population of , who need additional therapy to reduce their CV risk.

References

Show references

Find this article online at Lipid Journal

Share this page with your colleagues and friends: